Skyepharma invests in advanced R&D into tablet forms

Saint-Quentin-Fallavier, France: – Oral dosage specialist Skyepharma Productions S.A.S. (Skyepharma) has established an academic collaboration with the University of Bordeaux into tablet mechanical properties.

Skyepharma today announced a partnership with the University’s Laboratory of Galenic Pharmacy and Biopharmacy in association with the Institute of the Institute of Mechanical Engineering (I2M) joint research laboratory UMR 5295 jointly involving the University of Bordeaux, the French National Centre for Scientific Research (CNRS), and the Bordeaux INP that groups together eight of the region’s engineering graduate schools.

UMR 5295 comprises more than 320 staff in six research departments studying Physical Acoustics, Mechanical Engineering and Design, Civil and Environmental Engineering, Durability of Materials, Assemblies and Structures, Fluid Transfers, and Materials Processes & Interactions.

Tab-in-tab focus

The immediate focus of the collaboration will be on a PhD Thesis commencing in October, under the supervision of Professor Pierre Tchoreloff and Dr. Vincent Mazel, with scientific focus on ‘Mechanical resistance of pharmaceutical tablets tab-in-tab: characterisation and link with material and process parameters’.

Skyepharma’s Head of New Product Introduction, Aline Moulin, commented : “At Skyepharma we are very proud to invest in research and development. This new partnership will allow us to further expand our expertise in complex oral solid dosage forms.”

About Skyepharma Production

Skyepharma Production S.A.S. (Skyepharma) is a specialist CDMO with particular expertise and capabilities in oral solid dosage forms, being a key player in drug development and delivery of oral technologies serving the global pharmaceutical, biotech and consumer health industries.

Skyepharma is the oral business unit of the Vectura Group of companies, an international leader in inhalation and other drug delivery forms.

As an integrated CDMO, The company’s vision is to help solve healthcare industry complexity with a mission to provide a dedicated and results-oriented team to deliver advanced oral dosage services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationships. All of this is summed up in its strapline: ‘Expert and Agile CDMO partner for tailor-made solutions’.

The Skyepharma CDMO offer in solid oral dosage formats encompasses the whole value chain, including Formulation Development & Process Design, Analytical Development, Scale-up, Manufacturing, Packaging, Serialisation and Aggregation.

Skyepharma also provides a range of support services that help client companies from early stage development (up to phase III), through scale-up and full commercial manufacturing and packaging to market introduction, including controlled substance handling, QbD methodology (FMEA, FTA, DOE), Troubleshooting, regulatory services, validation, registration and warehousing services.